Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor.

Ben Haddou T, Malfacini D, Calo G, Aceto MD, Harris LS, Traynor JR, Coop A, Schmidhammer H, Spetea M.

Mol Pain. 2014 Jul 24;10:48. doi: 10.1186/1744-8069-10-48.

2.

Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible μ opioid receptor antagonist effects.

Moynihan HA, Derrick I, Broadbear JH, Greedy BM, Aceto MD, Harris LS, Purington LC, Thomas MP, Woods JH, Traynor JR, Husbands SM, Lewis JW.

J Med Chem. 2012 Nov 26;55(22):9868-74. doi: 10.1021/jm301096s. Epub 2012 Oct 31.

3.

l-theanine attenuates abstinence signs in morphine-dependent rhesus monkeys and elicits anxiolytic-like activity in mice.

Wise LE, Premaratne ID, Gamage TF, Lichtman AH, Hughes LD, Harris LS, Aceto MD.

Pharmacol Biochem Behav. 2012 Dec;103(2):245-52. doi: 10.1016/j.pbb.2012.08.008. Epub 2012 Aug 23.

4.

MDAN-21: A Bivalent Opioid Ligand Containing mu-Agonist and Delta-Antagonist Pharmacophores and Its Effects in Rhesus Monkeys.

Aceto MD, Harris LS, Negus SS, Banks ML, Hughes LD, Akgün E, Portoghese PS.

Int J Med Chem. 2012;2012:327257. doi: 10.1155/2012/327257. Epub 2012 Apr 29.

5.

Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexamines.

Cami-Kobeci G, Neal AP, Bradbury FA, Purington LC, Aceto MD, Harris LS, Lewis JW, Traynor JR, Husbands SM.

J Med Chem. 2009 Mar 26;52(6):1546-52. doi: 10.1021/jm8015552.

6.

The influence of esters and carboxylic acids as the N-substituent of opioids. Part 1: Benzomorphans.

Metcalf MD, Aceto MD, Harris LS, Woods JH, Traynor JR, Coop A, May EL.

Bioorg Med Chem. 2008 Jan 15;16(2):869-73. Epub 2007 Oct 13.

7.

Cinnamoyl derivatives of 7alpha-aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7alpha-aminomethyl-6,14-endo-ethanotetrahydrooripavine and related opioid ligands.

Rennison D, Neal AP, Cami-Kobeci G, Aceto MD, Martinez-Bermejo F, Lewis JW, Husbands SM.

J Med Chem. 2007 Oct 18;50(21):5176-82. Epub 2007 Sep 22.

8.

Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.

Hiebel AC, Lee YS, Bilsky E, Giuvelis D, Deschamps JR, Parrish DA, Aceto MD, May EL, Harris LS, Coop A, Dersch CM, Partilla JS, Rothman RB, Cheng K, Jacobson AE, Rice KC.

J Med Chem. 2007 Aug 9;50(16):3765-76. Epub 2007 Jul 11.

PMID:
17625813
9.

NIH 11082 produces anti-depressant-like activity in the mouse tail-suspension test through a delta-opioid receptor mechanism of action.

Naidu PS, Lichtman AH, Archer CC, May EL, Harris LS, Aceto MD.

Eur J Pharmacol. 2007 Jul 2;566(1-3):132-6. Epub 2007 Mar 30.

10.
11.

Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonists.

Cheng K, Kim IJ, Lee MJ, Adah SA, Raymond TJ, Bilsky EJ, Aceto MD, May EL, Harris LS, Coop A, Dersch CM, Rothman RB, Jacobson AE, Rice KC.

Org Biomol Chem. 2007 Apr 21;5(8):1177-90. Epub 2007 Mar 1.

PMID:
17406716
12.
13.

Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency.

Spetea M, Greiner E, Aceto MD, Harris LS, Coop A, Schmidhammer H.

J Med Chem. 2005 Jul 28;48(15):5052-5.

PMID:
16033285
14.

BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.

Husbands SM, Neilan CL, Broadbear J, Grundt P, Breeden S, Aceto MD, Woods JH, Lewis JW, Traynor JR.

Eur J Pharmacol. 2005 Feb 21;509(2-3):117-25.

PMID:
15733546
15.

Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan.

Srivastava SK, Shefali S, Miller CN, Aceto MD, Traynor JR, Lewis JW, Husbands SM.

J Med Chem. 2004 Dec 16;47(26):6645-8.

PMID:
15588100
16.

Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.

Carroll I, Thomas JB, Dykstra LA, Granger AL, Allen RM, Howard JL, Pollard GT, Aceto MD, Harris LS.

Eur J Pharmacol. 2004 Oct 6;501(1-3):111-9.

PMID:
15464069
17.

Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.

Neilan CL, Husbands SM, Breeden S, Ko MC, Aceto MD, Lewis JW, Woods JH, Traynor JR.

Eur J Pharmacol. 2004 Sep 19;499(1-2):107-16.

PMID:
15363957
18.

Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys.

Beardsley PM, Aceto MD, Cook CD, Bowman ER, Newman JL, Harris LS.

Exp Clin Psychopharmacol. 2004 Aug;12(3):163-72.

PMID:
15301633
19.

Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.

Spetea M, Schüllner F, Moisa RC, Berzetei-Gurske IP, Schraml B, Dörfler C, Aceto MD, Harris LS, Coop A, Schmidhammer H.

J Med Chem. 2004 Jun 3;47(12):3242-7.

PMID:
15163203
20.

Synthesis and biological evaluation of 14-alkoxymorphinans. 20. 14-phenylpropoxymetopon: an extremely powerful analgesic.

Schütz J, Spetea M, Koch M, Aceto MD, Harris LS, Coop A, Schmidhammer H.

J Med Chem. 2003 Sep 11;46(19):4182-7.

PMID:
12954070
21.

The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors.

Breivogel CS, Scates SM, Beletskaya IO, Lowery OB, Aceto MD, Martin BR.

Eur J Pharmacol. 2003 Jan 17;459(2-3):139-50.

PMID:
12524139
22.

N-(trifluoromethyl)benzyl substituted N-normetazocines and N-norketobemidones.

May EL, Coop A, Woods JH, Aceto MD, Bowman ER, Harris LS, Traynor JR.

Bioorg Med Chem. 2003 Jan 2;11(1):31-3.

PMID:
12467704
23.

Effects of the putative antagonist NCS382 on the behavioral pharmacological actions of gammahydroxybutyrate in mice.

Cook CD, Aceto MD, Coop A, Beardsley PM.

Psychopharmacology (Berl). 2002 Feb;160(1):99-106. Epub 2002 Jan 22.

PMID:
11862379
24.

4'-Arylpyrrolomorphinans: effect of a pyrrolo-N-benzyl substituent in enhancing delta-opioid antagonist activity.

Srivastava SK, Husbands SM, Aceto MD, Miller CN, Traynor JR, Lewis JW.

J Med Chem. 2002 Jan 17;45(2):537-40.

PMID:
11784158
25.

Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2.

Aceto MD, Scates SM, Martin BB.

Eur J Pharmacol. 2001 Mar 23;416(1-2):75-81.

PMID:
11282115
26.

Synthesis and in vitro and in vivo activity of (-)-(1R,5R,9R)- and (+)-(1S,5S,9S)-N-alkenyl-, -N-alkynyl-, and -N-cyanoalkyl-5, 9-dimethyl-2'-hydroxy-6,7-benzomorphan homologues.

May EL, Jacobson AE, Mattson MV, Traynor JR, Woods JH, Harris LS, Bowman ER, Aceto MD.

J Med Chem. 2000 Dec 28;43(26):5030-6.

PMID:
11150174
27.

N-Cyclohexylethyl-N-noroxymorphindole: a mu-opioid preferring analogue of naltrindole.

Coop A, Jacobson AE, Aceto MD, Harris LS, Traynor JR, Woods JH, Rice KC.

Bioorg Med Chem Lett. 2000 Nov 6;10(21):2449-51.

PMID:
11078198
28.

Dihydroetorphine: physical dependence and stereotypy after continuous infusion in the rat.

Aceto MD, Scates SM, Harris LS, Ji Z.

Eur J Pharmacol. 2000 Jan 3;387(1):31-7.

PMID:
10633157
29.

Antinociceptive and pharmacological effects of metanicotine, a selective nicotinic agonist.

Damaj MI, Glassco W, Aceto MD, Martin BR.

J Pharmacol Exp Ther. 1999 Oct;291(1):390-8.

PMID:
10490929
30.

Stereoselective mu- and delta-opioid receptor-related antinociception and binding with (+)-thebaine.

Aceto MD, Harris LS, Abood ME, Rice KC.

Eur J Pharmacol. 1999 Jan 22;365(2-3):143-7.

PMID:
9988096
31.

Anandamide, an endogenous cannabinoid, has a very low physical dependence potential.

Aceto MD, Scates SM, Razdan RK, Martin BR.

J Pharmacol Exp Ther. 1998 Nov;287(2):598-605.

PMID:
9808686
32.

3-Alkyl ethers of clocinnamox: delayed long-term mu-antagonists with variable mu efficacy.

Husbands SM, Sadd J, Broadbear JH, Woods JH, Martin J, Traynor JR, Aceto MD, Bowman ER, Harris LS, Lewis JW.

J Med Chem. 1998 Aug 27;41(18):3493-8.

PMID:
9719602
33.

Dependence studies of new compounds in the rhesus monkey, rat and mouse (1997).

Aceto MD, Bowman ER, Harris LS, May EL.

NIDA Res Monogr. 1998 Mar;178:363-407. No abstract available.

PMID:
9686404
34.

Etorphines: mu-opioid receptor-selective antinociception and low physical dependence capacity.

Aceto MD, Harris LS, Bowman ER.

Eur J Pharmacol. 1997 Nov 12;338(3):215-23.

PMID:
9424015
35.

Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal.

Aceto MD, Scates SM, Lowe JA, Martin BR.

J Pharmacol Exp Ther. 1996 Sep;278(3):1290-5.

PMID:
8819514
37.

Cocaine, ecgonine methyl ester, and benzoylecgonine plasma profiles in rhesus monkeys.

Saady JJ, Bowman ER, Aceto MD.

J Anal Toxicol. 1995 Nov-Dec;19(7):571-5.

PMID:
8577180
38.

Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.

Aceto MD, Scates SM, Lowe JA, Martin BR.

Eur J Pharmacol. 1995 Aug 25;282(1-3):R1-2.

PMID:
7498260
39.

Comparative pharmacology of nicotine and ABT-418, a new nicotinic agonist.

Damaj MI, Creasy KR, Welch SP, Rosecrans JA, Aceto MD, Martin BR.

Psychopharmacology (Berl). 1995 Aug;120(4):483-90.

PMID:
8539331
40.

Antipodal alpha-N-(methyl through decyl)-N-normetazocines (5,9 alpha-dimethyl-2'-hydroxy-6,7-benzomorphans): in vitro and in vivo properties.

May EL, Aceto MD, Bowman ER, Bentley C, Martin BR, Harris LS, Medzihradsky F, Mattson MV, Jacobson AE.

J Med Chem. 1994 Sep 30;37(20):3408-18.

PMID:
7932569
41.

Dependence studies of new compounds in the rhesus monkey, rat and mouse (1993).

Aceto MD, Bowman ER, Harris LS, May EL.

NIDA Res Monogr. 1994;140:103-78. No abstract available.

PMID:
8722464
42.

Cocaine-induced rausch: overt behaviour and plasma concentrations in rhesus monkeys.

Saady JJ, Bowman ER, Aceto MD.

Eur J Drug Metab Pharmacokinet. 1994 Jan-Mar;19(1):41-6.

PMID:
7957451
43.

Nicotine's opioid and anti-opioid interactions: proposed role in smoking behavior.

Aceto MD, Scates SM, Ji Z, Bowman ER.

Eur J Pharmacol. 1993 Dec 1;248(4):333-5.

PMID:
8181540
44.
45.

Dependence studies of new compounds in the rhesus monkey, rat and mouse (1992).

Aceto MD, Bowman ER, Harris LS, May EL.

NIDA Res Monogr. 1993;132:459-516. Review. No abstract available.

PMID:
8341373
46.

Blockade of dynorphin A(1-13) overt psychomotor effects by naloxone.

Aceto MD, Bowman ER.

Peptides. 1992 Jul-Aug;13(4):847-9.

PMID:
1359510
47.

Functional and dispositional tolerance develops during continuous cocaine exposure.

Johansson EK, Tucker SM, Ginn HB, Martin BR, Aceto MD.

Eur J Drug Metab Pharmacokinet. 1992 Apr-Jun;17(2):155-62.

PMID:
1425814
48.

Dependence studies of new compounds in the rhesus monkey and mouse (1991).

Aceto MD, Bowman ER, Harris LS, May EL.

NIDA Res Monogr. 1992;119:513-58. Review. No abstract available.

PMID:
1435984
49.

Dependence studies of new compounds in the rhesus monkey and mouse (1990).

Aceto MD, Bowman ER, Harris LS, May EL.

NIDA Res Monogr. 1990;105:640-81. Review.

PMID:
1876150
50.

Common stereospecificity of opioid and dopamine systems for N-butyrophenone prodine-like compounds.

Iorio MA, Frigeni V, Bowman ER, Harris LS, May EL, Aceto MD.

J Med Chem. 1991 Jan;34(1):194-7.

PMID:
1671414

Supplemental Content

Loading ...
Support Center